Growth kinetics of CD133-positive prostate cancer cells

Prostate

Volumn 73, Issue 7, 2013, Pages 724-733

  Reyes, Edwin E ^a   Kunovac, Stefan K ^b   Duggan, Ryan ^a   Kregel, Steven ^a   Griend, Donald J Vander ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

Author keywords

androgen receptor; cancer stem cell; castration resistance; CD133; cell cycle; G2 phase; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; CD133 ANTIGEN; DNA; METRIBOLONE;

ARTICLE; CANCER GROWTH; CELL CYCLE; CELL CYCLE PROGRESSION; CELL DENSITY; CELL DIVISION; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANTIGENS, CD; CELL CYCLE; CELL LINE, TUMOR; FLOW CYTOMETRY; GLYCOPROTEINS; HUMANS; KINETICS; MALE; PEPTIDES; PROSTATE; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84876293266     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22616     Document Type: Article

References (37)

1. Siegel R, Ward E, Brawley O, Jemal A,. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61 (4): 212-236.
2. Wicha MS, Liu S, Dontu G,. Cancer stem cells: An old idea-A paradigm shift. Cancer Res 2006; 66 (4): 1883-1890; discussion 1895-1886.
3. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ,. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65 (23): 10946-10951.
4. Gu G, Yuan J, Wills M, Kasper S,. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007; 67 (10): 4807-4815.
5. Patrawala L, Calhoun-Davis T, Schneider-Broussard R, Tang DG,. Hierarchical organization of prostate cancer cells in xenograft tumors: The CD44+{alpha}2{beta}1+ cell population is enriched in tumor-initiating cells. Cancer Res 2007; 67 (14): 6796-6805.
6. Vander Griend DJ, Karthaus WK, Dalrymple S, Meeker AK, De Marzo AM, Isaacs JT,. The role of CD133 in normal human prostate stem cells and malignant cancer initiating cells. Cancer Res 2008; 68 (23): 9703-9711.
7. Sharifi N, Hurt EM, Farrar WL,. Androgen receptor expression in prostate cancer stem cells: Is there a conundrum? Cancer Chemother Pharmacol 2008; 62 (5): 921-923.
8. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D, Tang DG,. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011; 17 (2): 211-215.
9. Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, Calhoun-Davis T, Li H, Palapattu GS, Pang S, Lin K, Huang J, Ivanov I, Li W, Suraneni MV, Tang DG,. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012; 10 (5): 556-569.
10. Mizrak D, Brittan M, Alison MR,. CD133: Molecule of the moment. J Pathol 2008; 214 (1): 3-9.
11. Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB,. Prominin: A story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001; 2 (2): 82-91.
12. Hess DA, Wirthlin L, Craft TP, Herrbrich PE, Hohm SA, Lahey R, Eades WC, Creer MH, Nolta JA,. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 2006; 107 (5): 2162-2169.
13. Kania G, Corbeil D, Fuchs J, Tarasov KV, Blyszczuk P, Huttner WB, Boheler KR, Wobus AM,. Somatic stem cell marker prominin-1/CD133 is expressed in embryonic stem cell-derived progenitors. Stem Cells 2005; 23 (6): 791-804.
14. Bauer N, Fonseca AV, Florek M, Freund D, Jaszai J, Bornhauser M, Fargeas CA, Corbeil D,. New insights into the cell biology of hematopoietic progenitors by studying prominin-1 (CD133). Cells Tissues Organs 2007; 188 (1-2): 127-138.
15. Collins AT, Habib FK, Maitland NJ, Neal DE,. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci 2001; 114 (Pt 21): 3865-3872.
16. Hudson DL, O'Hare M, Watt FM, Masters JR,. Proliferative heterogeneity in the human prostate: Evidence for epithelial stem cells. Lab Invest 2000; 80 (8): 1243-1250.
17. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT,. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117 (Pt 16): 3539-3545.
18. Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, Isaacs JT,. Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res 2006; 66 (17): 8598-8607.
19. van Bokhoven A, Varella-Garcia M, Korch C, Johannes WU, Smith EE, Miller HL, Nordeen SK, Miller GJ, Lucia MS,. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003; 57 (3): 205-225.
20. Wu Y, Wu PY,. CD133 as a marker for cancer stem cells: Progresses and concerns. Stem Cells Dev 2009; 18 (8): 1127-1134.
21. Craft N, Shostak Y, Carey M, Sawyers CL,. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5 (3): 280-285.
22. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E,. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992; 41 (3-8): 665-669.
23. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ,. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 2008; 68 (13): 5469-5477.
24. Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT,. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003; 54 (4): 249-257.
25. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ,. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002; 62 (22): 6606-6614.
26. Vander Griend DJ, D'Antonio JM, Gurel B, Antony L, De Marzo AM, Isaacs JT,. Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate 2010; 70 (1): 90-99.
27. Cunha GR, Alarid ET, Turner T, Donjacour AA, Boutin EL, Foster BA,. Normal and abnormal development of the male urogenital tract. Role of androgens, mesenchymal-epithelial interactions, and growth factors. J Androl 1992; 13 (6): 465-475.
28. Isaacs JT,. Role of androgens in prostatic cancer. Vitam Horm 1994; 49: 433-502.
29. Chen Y, Sawyers CL, Scher HI,. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8 (4): 440-448.
30. Bonkhoff H, Berges R,. From pathogenesis to prevention of castration resistant prostate cancer. Prostate 2009; 70 (1): 100-112.
31. Ferrandina G, Petrillo M, Bonanno G, Scambia G,. Targeting CD133 antigen in cancer. Expert Opin Ther Targets 2009; 13 (7): 823-837.
32. Shepherd CJ, Rizzo S, Ledaki I, Davies M, Brewer D, Attard G, de Bono J, Hudson DL,. Expression profiling of CD133(+) and CD133(-) epithelial cells from human prostate. Prostate 2008; 68 (9): 1007-1024.
33. Malumbres M, Pevarello P, Barbacid M, Bischoff JR,. CDK inhibitors in cancer therapy: What is next? Trends Pharmacol Sci 2008; 29 (1): 16-21.
34. Rowehl RA, Crawford H, Dufour A, Ju J, Botchkina GI,. Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line. Cancer Genomics Proteomics 2008; 5 (6): 301-310.
35. O'Brien CA, Pollett A, Gallinger S, Dick JE,. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445 (7123): 106-110.
36. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R,. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445 (7123): 111-115.
37. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R,. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009; 27 (12): 2875-2883.